Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats CMV retinitis. Sold as Valcyte. Every FDA application for this active ingredient: 2 branded and 19 generic.
As of Nov 16, 2026, FDA lists 21 applications for Valganciclovir Hydrochloride (sold as Valcyte), first approved Mar 29, 2001, with 7 new uses approved and 0 published complete response letters.
First approved: Mar 29, 2001
Applications: 21
New uses approved: 7
Complete response letters: 0
Medicare spending, 2025: $27.8M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Valganciclovir HCl
Part D
$27.6M
-1%
33,718
Valcyte
Part D
$144K
+69%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
VALGANCICLOVIR 450 MG TABLET: $1.84 per unitGeneric · -26% in a year
VALGANCICLOVIR HCL 50 MG/ML: $1.03 per MLGeneric · -11% in a year
ValixaA drug with a new indication and a new dosage for the treatment of symptomatic congenital cytomegalovirus infection. · Mitsubishi Tanabe Pharma Corporation · Mar 27, 2023 · Review report
ValixaA drug with a new additional indication and a new dosage for the prevention of cytomegalovirus disease in organ transplant patients (excluding hematopoietic… · Mitsubishi Tanabe Pharma Corporation · Aug 26, 2016
ValixaA drug with a new additional indication for the treatment of cytomegalovirus infection in organ transplantation (including hematogenic stem cell… · Mitsubishi Tanabe Pharma Corporation · May 20, 2009
Clinical Trials
33 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
CMV-CMI in csCMVi After HSCTCytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT) · The First Affiliated Hospital of Soochow University
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA